药物抑制铁死亡抗心肌缺血-再灌注损伤及机制研究进展  

Research Progress on the Mechanism of Drugs Inhibiting Ferroptosis for the Treatment of Myocardial Ischemia-Reperfusion Injury

作　　者：寇世杰 陈士萍 KOU Shijie;CHEN Shiping(Department of Cardiology,the Affiliated Hospital of Chifeng University,Chifeng 024005,China)

机构地区：[1]赤峰学院附属医院心内科,赤峰024005

出　　处：《医药导报》2023年第4期519-523,共5页Herald of Medicine

基　　金：内蒙古自治区高校科研项目(NJZY19218)。

摘　　要：心肌缺血-再灌注损伤(MIRI)是急性心肌梗死不可避免的危险事件。铁死亡是一种铁依赖、过氧化物驱动、非凋亡形式的调节性细胞死亡方式,其参与MIRI的发病机制。研究显示药物靶向抑制铁死亡能够防治MIRI。但目前尚缺乏总结通过铁死亡机制来干预MIRI药物的综述。因此,该文按照调控GPX4、调控铁和抑制脂质过氧化三种抑制铁死亡机制治疗MIRI的药物进行了分类和整理,并系统阐述了抑制铁死亡减轻MIRI药物的最新研究进展,药物靶向抑制铁死亡可作为MIRI治疗的潜在新靶点。Myocardial ischemia-reperfusion injury(MIRI)is an unavoidable risk event for acute myocardial infarction.Ferroptosis was an iron dependent,peroxide-driven,nonapoptotic form of regulatory cell death.Accumulating evidences have suggested that ferroptosis may play a vital role in the pathogenic progression of MIRI.Notably,targeted inhibitors can alleviate MIRI by blocking the ferroptosis pathway.Despite these advances,a systematical review summarizing the intervention of ferroptosis inhibitors in modulating ferroptosis in MIRI is still lacking to date.Herein,this review summarizes the emerging data from different models that have studied in mitigating MIRI through pharmacologically inducing ferroptosis.Therefore,this paper classifies and organizes drugs that inhibit ferroptosis in the treatment of MIRI according to three mechanisms:regulating GPX4,regulating iron,and inhibiting lipid peroxidation.This review suggests that the pharmacological inhibition of ferroptosis by bioactive compounds can be used as a therapeutic target for MIRI.

关 键 词：铁死亡抑制剂 心肌缺血-再灌注损伤 铁死亡 心肌保护 

分 类 号：R542.2[医药卫生—心血管疾病]